» Articles » PMID: 22573503

Leukocytosis As an Important Risk Factor for Arterial Thrombosis in WHO-defined Early/prefibrotic Myelofibrosis: an International Study of 264 Patients

Abstract

We aimed to determine risk factors for thrombotic events in early/prefibrotic myelofibrosis diagnosed according to the World Health Organization criteria. Multivariate Cox regression analysis was calculated on a total number of 264 patients derived from an international database. After a median follow-up of 6.28 years, 42 (15.9%) patients experienced arterial (n = 31) or venous thrombosis (n = 11). A higher leukocyte count correlated with an increased risk for total thrombosis and in particular, with an increased risk for arterial thrombosis (P = 0.005, HR 1.15 and P = 0.047, HR 1.12, respectively). A platelet count above 870 × 10⁹/L was associated with a lower risk for total thrombosis and also for venous thrombosis (P = 0.022, HR 0.44 and P = 0.027, HR 0.19). Moreover, a lower hemoglobin level was associated with an increased risk for venous thrombosis (P = 0.007, HR 0.59). Our data indicate that leukocytosis is a prominent risk factor for thrombosis in early/prefibrotic MF.

Citing Articles

A randomized, double-blind, placebo-controlled phase 3 study to assess efficacy and safety of ropeginterferon alfa-2b in patients with early/lower-risk primary myelofibrosis.

Abu-Zeinah G, Qin A, Gill H, Komatsu N, Mascarenhas J, Shih W Ann Hematol. 2024; 103(9):3573-3583.

PMID: 39145781 PMC: 11358163. DOI: 10.1007/s00277-024-05912-8.


Prediction of acute coronary syndrome in patients with myeloproliferative neoplasms.

Huang J, Zhang P, Shen F, Zheng X, Ding Q, Pan Y Front Cardiovasc Med. 2024; 11:1369701.

PMID: 38984355 PMC: 11231400. DOI: 10.3389/fcvm.2024.1369701.


Evaluation of Absolute Neutrophil, Lymphocyte and Platelet Count and Their Ratios as Predictors of Thrombotic Risk in Patients with Prefibrotic and Overt Myelofibrosis.

Lucijanic M, Krecak I, Soric E, Sabljic A, Galusic D, Holik H Life (Basel). 2024; 14(4).

PMID: 38672793 PMC: 11051164. DOI: 10.3390/life14040523.


Effective Management of Polycythemia Vera With Ropeginterferon Alfa-2b Treatment.

Suo S, Fu R, Qin A, Shao Z, Bai J, Chen S J Hematol. 2024; 13(1-2):12-22.

PMID: 38644985 PMC: 11027776. DOI: 10.14740/jh1245.


From Budd-Chiari syndrome to acquired von Willebrand syndrome: thrombosis and bleeding complications in the myeloproliferative neoplasms.

Stein B, Martin K Hematology Am Soc Hematol Educ Program. 2019; 2019(1):397-406.

PMID: 31808903 PMC: 6913438. DOI: 10.1182/hematology.2019001318.